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A lkaline phosphatase (ALP) is an enzyme that cat-alyzes the hydrolysis of monophosphate esters 
under alkaline pH conditions [1].  ALP is expressed in 
various tissues.  The concentrations of ALP are highest 
in the bone and liver,  and they are also high in tissues of 
the intestines,  kidney,  testes,  and syncytiotrophoblasts 
[2].  Human ALP is classified into four isozymes:  
tissue-nonspecific isozyme ALP (TNALP,  i.e.,  bone-,  
liver- and kidney-specific ALP),  intestinal-type ALP 
(IALP),  placental-type ALP,  and placental-like ALP 
[2 , 3].
Serum ALP levels are affected by various diseases,  
but in some cases,  the sources of ALP can be character-
ized by their isozymes.  In clinical practice,  the serum 
level of ALP is used mostly as a marker for bone and 
hepatic diseases [4].  Serum ALP levels are increased 
not only in hepatic diseases such as cirrhosis and 
chronic hepatitis but also in the bilious disorders such as 
choledocholithiasis and sclerosing cholangitis [3].  
Serum ALP levels also tend to be increased in embry-
onic and testicular diseases such as ovarian and testicu-
lar cancers [2].
Bone-specific alkaline phosphatase (BAP) levels are 
greatly affected by humoral factors that have effects on 
bone formation and resorption [5 , 6].  The turnover of 
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Alkaline phosphatase (ALP) is an enzyme that is expressed in a variety of tissues.  Among the isoforms of ALP,  
bone-specific alkaline phosphatase (BAP) is used as a marker for evaluating bone metabolism.  We investigated 
the clinical usefulness of the ratio of serum BAP to total ALP for the diagnosis of various disorders in general 
practice.  We retrospectively analyzed the cases of 107 Japanese patients whose serum BAP levels were exam-
ined,  focusing on clinical characteristics.  We observed that the BAP/ALP ratios of the patients with fever and 
those with inflammatory diseases were significantly lower than the ratios of other patient groups.  The BAP/
ALP ratios of the patients with osteoporosis and those with metabolic bone diseases were higher than those of 
the patients with other conditions.  The BAP/ALP ratio was found to be negatively correlated with age,  a cor-
relation that has not been found in other ethnicities.  The serum BAP/ALP ratio was inversely correlated with 
serum CRP levels but was positively correlated with serum albumin levels and hemoglobin concentrations.  
Collectively,  our results suggest that the BAP/ALP ratio could be a useful predictor for important geriatric con-
ditions seen in general practice.
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bone metabolism is regulated by various factors includ-
ing parathyroid hormone (PTH),  vitamin D,  and sex 
steroids [7].  Recent studies have further suggested an 
association between the serum ALP levels and the risk 
of cardiovascular or renal damage [8 , 9].
There have been several studies in which the rela-
tionships between serum levels of ALP and diseases of 
tissues related to the isozymes have been analyzed.  
However,  there has been no study evaluating the rele-
vance of serum ALP levels to a variety of chief com-
plaints,  general conditions,  and/or co-existing compli-
cations.  In the present study,  we investigated the 
comparative levels of the bone isoform of serum ALP to 
determine the clinical usefulness of BAP and its appli-
cation for the differential diagnoses of various disorders 
seen in general practice.
Patients and Methods
Patients. We retrospectively analyzed the medi-
cal records of 107 patients whose serum BAP and ALP 
levels were examined at the Department of General 
Medicine,  Okayama University Hospital during the 
period from January 2016 to September 2019.  The 
patients were 45 males and 62 females with a mean±SD 
age of 58.5 ± 17.5 years (range,  18-94 years).
We classified the patients into the following six 
groups based on their chief complaints: (1) the symp-
tom-free group,  (2) the pain group (including patients 
with somatic pain such as headache,  myalgia,  lumbago,  
arthralgia,  and various types of visceral pain),  (3) the 
psychological group (including patients with depres-
sion,  sleep disorder,  mood disorder,  or anorexia),  (4) 
the fever group (patients with body temperature 
> 37.5°C),  (5) the weight gain group (including obese 
patients and patients with edema),  and (6) the urinary 
symptom group (including patients with pollakisuria,  
urinary discomfort,  or incontinence).  The patients 
were also classified into 6 groups based on their primary 
diseases: (1) metabolic bone diseases,  (2) nephrologi-
cal and endocrine diseases,  (3) primary osteoporosis,  
(4) inflammatory diseases,  (5) hematologic and onco-
logic diseases,  and (6) nervous system and psychologi-
cal diseases.  The patients’ chief complaints and the 
primary diseases were assessed from electronic medical 
records by 2 or 3 of the study’s authors.
In another study,  all of the patients were classified 
into 3 groups depending on their febrile symptoms as 
follows: fever,  fever-free,  and symptom-free groups.  
They were also classified into 2 groups based on the lev-
els of inflammatory markers: high erythrocyte sedi-
mentation rate (ESR; > 15 mm) versus low ESR groups 
(≤ 15 mm) and high C-reactive protein (CRP; > 0.15 
mg/dl) versus low CRP groups (≤ 0.15 mg/dl).  The 
patients were also divided into groups according to 
whether they had the following complications: hyper-
tension,  dyslipidemia,  diabetes mellitus,  and osteopo-
rosis.
The study protocol was approved by the Institutional 
Review Board (IRB) of Okayama University Graduate 
School of Medicine,  Dentistry and Pharmaceutical 
Sciences (#K1907-018).
Laboratory examinations. Each patient’s ESR 
and serum levels of BAP,  ALP,  CRP,  albumin,  and 
hemoglobin had been determined by an auto-analyzer 
system in the Central Laboratory of Okayama 
University Hospital.  Serum ALP levels (U/l) were 
determined according to the standard method of the 
Japan Society of Clinical Chemistry (JSCC),  and serum 
BAP levels (µg/l) were measured using the chemilumi-
nescent enzyme immunoassay (CLEIA) method.  Serum 
BAP levels (µg/l) measured by the CLEIA method were 
converted to enzyme units (U/l) using the following 
formula with a correlation coefficient of 0.962 [10]:  
BAP (U/l) = (BAP (µg/l) + 2.265)/0.733.  The serum CRP 
levels (mg/dl) were determined by a latex-agglutination 
method using latex particles conjugated with anti-CRP 
antiserum,  and the normal range was ≤ 0.15 mg/dl.  
The femoral young adult mean (YAM) was calculated 
using the patient’s femoral bone mineral density,  which 
was measured by a DXA system called Horizon-type A 
(140/100 kVp,  2.5 mA,  82 sec; Hologic,  Marlborough,  
MA,  USA) at Okayama University Hospital [11].
Statistical analysis. Results are shown as the 
mean±SEM of data.  The Steel-Dwass test,  one-way 
analysis of variance (ANOVA),  and Mann-Whitney 
U-test were used to determine significant differences 
between pairs of groups.  If differences were detected by 
the one-way ANOVA,  the Tukey post-hoc test was used 
to determine which means differed.  Spearman’s rank 
correlation coefficients were also used to determine 
inter-relationships between parameters.  P-values < 0.05 
were accepted as significant.  All statistical analyses 
were performed with EZR,  which is a graphical user 
interface for R [12].
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Results
Patients’ characteristics. All of the patients were 
first categorized by their symptoms (one chief complaint 
per patient).  The number of patients was largest in the 
symptom-free group (n = 33,  30.8%) followed by the 
pain group (n = 32,  29.9%),  the psychological group 
(n = 20,  18.7%),  the symptoms related to fever group 
(n = 8,  7.5%),  the weight gain group (n = 7,  6.5%),  and 
the urinary symptom group (n = 7,  6.5%).  The percent-
ages of females in the six symptom-based groups (53.1-
70.0%) were slightly higher than the percentages of 
males.
The patients were also classified by disease-based 
categories (one major disease per patient).  The number 
of patients with metabolic bone diseases (n = 27,  25.2%) 
was the largest,  followed by patients with nephrological 
and endocrine diseases (n = 24,  22.4%),  primary osteo-
porosis (n = 17,  15.9%),  inflammatory diseases (n = 15,  
15.0%),  hematologic or oncologic diseases (n = 14,  
13.1%),  and nervous system or psychological diseases 
(n = 10,  9.3%).  The percentages of female patients were 
higher than the percentages of male patients in the cat-
egories of primary osteoporosis (82.4%),  nervous sys-
tem and psychological diseases (80.0%),  and metabolic 
bone diseases (66.7%).  The demographic data for the 
symptom-based and disease-based categories are shown 
in Table 1.
Gender-dependent distribution of serum BAP and 
BAP/ALP levels. The age and gender distributions of 
the patients are shown in Fig. 1A.  As stated above,  the 
patients were 45 males (42.1%) and 62 females (57.9%).  
In both the males and females,  the largest numbers of 
patients were in the age range of 51-70 years 
(males: n = 20,  44.4%; females: n = 21,  33.9%),  and 
the proportions of patients under 30 years of age were 
small (males: n = 5,  11.1%; females: n = 2,  3.2%).  
Female patients were dominant in the age ranges of 
31-50 years and > 71 years (Fig. 1A).  As shown in 
Fig. 1B,  the serum levels of BAP (p = 0.729) and ALP 
(p = 0.532) were not significantly different between the 
male and female patients,  although the ratios of BAP/
ALP in the female patients tended to be high (p = 0.257) 
compared to those in the male patients.
Category-based distributions of serum BAP and 
ALP levels and BAP/ALP ratios. The serum BAP 
and ALP levels and the BAP/ALP ratios were examined 
by symptom-based categories as shown in Fig. 2A.  The 
serum levels of BAP and ALP were not significantly 
different among the 6 groups of symptom-based catego-
ries.  However,  the BAP/ALP ratio in the fever group 
(p = 0.013) was significantly lower than that in the 
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Table 1　 Demographic data for symptom-based and disease-based categories
Age Male (%) Female (%) Number
Symptom-baed categories
　Symptom-free group 58.4±17.0 15 (45.5) 18 (54.5) 33
　Pain group 59.9±16.1 15 (46.9) 17 (53.1) 32
　Psychologic group 49.7±18.4 6 (30.0) 14 (70.0) 20
　Fever group 60.6±19.0 3 (37.5) 5 (62.5) 8
　Weight gain group 66.4±23.0 3 (42.9) 4 (57.1) 7
　Urinary symptom group 67.6±7.3 3 (42.9) 4 (57.1) 7
　　Total 58.5±17.5 45 (42.1) 62 (57.9) 107
Age Male (%) Female (%) Number
Disease-based categories
　Metabolic bone diseases 59.4±11.9 9 (33.3) 18 (66.7) 27
　Nephrological and endocrine diseases 53.7±18.5 14 (58.3) 10 (41.7) 24
　Primary osteoporosis 61.0±19.7 3 (17.6) 14 (82.4) 17
　Inflammatory diseases 65.2±13.3 9 (60.0) 6 (40.0) 15
　Hematologic and oncologic diseases 66.0±16.2 8 (57.1) 6 (42.9) 14
　Nervous system and psychological diseases 42.8±21.5 2 (20.0) 8 (80.0) 10
　　Total 58.5±17.5 45 (42.1) 62 (57.9) 107



















































































































































































































Fig. 1　 Serum BAP and ALP levels,  BAP/ALP ratios,  and gender differences.  A,  Age distributions of the male and female patients;  
B,  Comparison of the BAP and ALP levels and BAP/ALP ratios by gender.  Bars: mean±SEM.  The data were analyzed by the Mann-
Whitney U-test.
Fig. 2　 Serum BAP and ALP 
levels and BAP/ALP ratios in 
symptom-based and disease- 
based categories.  A,  Comparison 
of the BAP and ALP levels and 
BAP/ALP ratios among the six 
symptom-based groups; B,  BAP 
and ALP levels and the BAP/ALP 
ratios among the six disease- 
based groups.  Bars: mean±
SEM.  The data were analyzed by 
the Steel-Dwass test (for BAP and 
ALP) and ANOVA (for BAP/ALP 
ratio).  ＊p <0.05,  ＊＊p <0.01 
between the indicated groups.
symptom-free group (Fig. 2A).  Figure 2B provides the 
distributions of serum BAP and ALP levels and BAP/
ALP ratios in the disease-based categories.  The serum 
BAP levels in the metabolic bone disease group (p=0.034) 
and the primary osteoporosis group (p = 0.018) were 
significantly higher than the level in the group of neu-
rologic and psychological diseases.  The serum levels of 
ALP were not significantly different among the six dis-
ease-based categories.  The serum BAP/ALP ratios in 
the groups of metabolic bone disease (p = 0.0033) and 
primary osteoporosis (p = 0.0031) were significantly 
higher than those in the group of inflammatory diseases,  
and the serum BAP/ALP ratios in the groups of meta-
bolic bone disease (p = 0.020) and primary osteoporosis 
(p = 0.018) were also significantly higher than the ratio 
in the group of hematologic and oncologic diseases 
(Fig. 2B).
The relationships of the BAP/ALP ratio with 
inflammatory markers and complications. As 
shown in Fig. 3A,  the serum BAP/ALP ratio in the fever 
group was significantly lower than the ratios in the 
symptom-free (p = 0.00037) and fever-free (p = 0.0011) 
groups.  Figure 3B illustrates the relationships between 
the BAP/ALP ratio and inflammatory markers.  The 
BAP/ALP ratios were not significantly different (p=0.21) 
between the high ESR group (> 15 mm) and the low ESR 
group (≤ 15 mm),  whereas the BAP/ALP ratio in the 
high CRP group (> 0.15 mg/dl) was significantly lower 
(p = 0.00038) than that in the low CRP group (≤ 0.15 
mg/dl).  Figure 3C shows the differences in BAP/ALP 
ratios with respect to major complications.  There were 
no significant differences in BAP/ALP ratios among the 
patients with hypertension (p = 0.057),  dyslipidemia 
(p = 0.85),  and diabetes mellitus (p= 0.79),  but the BAP/
ALP ratio of the patients with osteoporosis was signifi-
cantly higher (p= 0.028) than that of the patients without 
osteoporosis.
Inter-relationships between the BAP/ALP ratio and 
the related factors. The inter-relationships between 
the BAP/ALP ratio and age,  serum levels of CRP and 



















































































≦ 0.15 > 15 ≦ 0.15 > 0.15Symp ー ＋ー
ー ＋
ESR (mm) CRP (mg/dl)Fever
Hypertension Dyslipidemia






Fig. 3　 Comparison of BAP/ALP ratios in the presence and absence of inflammation and complications.  A,  Comparison of BAP/ALP 
ratios by fever among the fever group (n=9),  the fever-free group (n=98),  and the symptom-free group (n=33); B,  The BAP/ALP ratios 
based on the levels of inflammatory markers among the high ESR group (>15 mm,  n=21),  low ESR group (≤15 mm,  n=14),  high CRP 
group (>0.15 mg/dl,  n=42) and low CRP group (≤0.15 mg/dl,  n=56); C,  BAP/ALP ratios based on complications including hyperten-
sion (−: n=73 and +: n=34),  dyslipidemia (−: n=85 and +: n=22),  diabetes mellitus (−: n=90 and +: n=17),  and osteoporosis 
(−: n=39 and +: n=68).  The data were analyzed by ANOVA (A) or the Mann-Whitney U-test (B,C).  ＊p<0.05,  ＊＊p<0.01 between the 
indicated groups.
albumin,  and hemoglobin concentration are shown in 
Fig. 4.  The serum BAP/ALP ratio was negatively cor-
related with age (R = − 0.285,  p = 0.00294,  n = 107) and 
the serum CRP level (R= − 0.453,  p= 0.0000027,  n= 98).  
On the other hand,  the serum BAP/ALP ratio was pos-
itively correlated with the serum albumin level 
(R = 0.429,  p = 0.0000061,  n = 103) and the hemoglobin 
concentration (R = 0.336,  p = 0.00043,  n = 107).
Discussion
As noted above,  BAP is a marker of bone formation 
[6].  The results of our present study,  in which the data 
of patients who visited a general medicine outpatient 
clinic were investigated,  provide a new perspective on 
the potential roles of BAP.  First,  the serum BAP/ALP 
ratios of the patients with fever and those with inflam-
matory diseases were significantly lower than those of 
the other groups of patients.  Second,  the BAP/ALP 
ratios of the patients with primary osteoporosis and 
those with metabolic bone diseases were significantly 
higher than those of the patients with other disorders.  
Third,  the BAP/ALP ratio had significant correlations 
with aging and with anabolic and inflammatory factors.
It was notable that the BAP/ALP ratios of the 
patients with fever and the patients with inflammatory 
diseases were lower than those of the patients with other 
disorders.  Lower serum BAP/ALP ratios indicate that 
the contribution of the activity of BAP to the total ALP 
activities is relatively small.  We observed an inverse 
correlation between the serum BAP/ALP ratio and the 
serum CRP level,  in addition to the relationships of the 
BAP/ALP ratio with fever and inflammation.  The 
results of several experimental studies suggested an 
inter-relationship between systemic inflammation and 
ALP activity.  An in vitro study using mouse osteoblastic 
cells revealed that elevated CRP suppressed the activity 
of runt-related transcription factor 2 (Runx2) as a tran-
scription factor of TNALP mRNA,  leading to a 
decrease of BAP activity [13].  It was also demonstrated 












































































R=0.336  ＊＊P<0.01 (n=107)
R=-0.453  ＊＊P<0.01 (n=98)
Fig. 4　 Inter-relationships between the serum BAP/ALP ratio and changes in related markers.  Correlations between the serum BAP/ALP 
ratio and the patientsʼ age (years,  n=107),  serum CRP level (mg/dl,  n=98),  albumin level (g/dl,  n=103),  and hemoglobin concentra-
tion (g/dl,  n=107) were analyzed by Spearmanʼs rank correlation coefficients.  ＊＊p<0.01 between the indicated factors.
that in vitro,  tumor necrosis factor stimulates BAP 
activity [14],  leading to vascular calcification.
In a mouse model of sepsis or acute inflammation,  it 
was shown that the levels of IALP and liver-specific 
TNALP are elevated [15],  and it was reported that IALP 
may mitigate inflammatory responses through the 
dephosphorylation of proinflammatory ATP [16].  Thus,  
various types of ALP isozymes,  as total ALP activity,  
are increased in inflammatory conditions,  and these 
increases may lead to a decreased BAP/ALP ratio in 
patients with inflammatory diseases.  The BAP/ALP 
ratio may thus be a useful indicator of systemic inflam-
mation.
Regarding the relationship between the serum BAP/
ALP ratio and aging,  it is known that the serum BAP 
level does not necessarily decrease with aging,  whereas 
the bone turnover tends to be low in elderly people [17].  
Several investigations have shown variations in the BAP 
level depending on ethnicity.  According to a report by 
Zhao et al.,  the BAP levels were highest in the age group 
of 20-29 years and reached a plateau in the age group of 
50-59 years [18].  An Italian study suggested that BAP 
levels do not differ depending on age [19].  According to 
a recent Japanese study,  a high BAP level might be an 
effective indicator of future cardiovascular events and 
the extent of vascular calcification [20].
Although it has been suggested in previous reports 
that the BAP level might be stable in people past their 
60s,  no report has described the age-related patterns of 
BAP in a Japanese population.  In our present study of 
Japanese patients,  a negative correlation was found 
between age and the BAP/ALP ratio.  The present 
results suggest that the BAP levels in Japanese people 
decrease with aging,  which may be different from other 
ethnicities.
On the other hand,  our analyses revealed that the 
BAP/ALP ratios of the patients with primary osteopo-
rosis and those with other metabolic bone diseases 
tended to be higher than those of the patients with 
other conditions.  High-turnover osteoporosis,  such as 
postmenopausal osteoporosis,  has been shown to not 
only activate bone formation but also increase bone 
resorption [21],  which might have led to an increase in 
the serum BAP level.  As for metabolic bone disorders,  
it was shown that high serum PTH levels abnormally 
stimulate born turnover in patients with primary 
hyperparathyroidism,  resulting in elevated serum BAP 
levels [22].  Osteomalacia can also result in the develop-
ment of secondary hyperparathyroidism,  which also 
contributes to a high serum BAP level [23].  In the pres-
ent study,  the patients complicated with osteoporosis 
(Fig. 3C) included not only patients with primary oste-
oporosis but also patients with secondary osteoporosis 
due to metabolic bone disorders,  such as primary 
hyperparathyroidism,  osteomalacia,  and Paget’s disease 
of the bone and multiple myeloma.  Thus,  the BAP/
ALP ratios of the present patients with osteoporosis 
might have been relatively high.
Taking the present findings together,  we propose 
that the BAP/ALP ratio is also a useful marker for esti-
mating generalized bone metabolism.  The serum albu-
min level is considered a critical nutritional index [24] 
and has been shown to decrease with aging [25].  The 
hemoglobin concentration also decreases with age [26].  
Considering these points,  we speculate that the BAP/
ALP ratio could be one of the parameters indicating 
geriatric disorders,  which include a wide range of con-
ditions representing multiple organ impairment in older 
people.
Collectively,  our results indicate the clinical rele-
vance of the serum BAP and ALP levels to various chief 
complaints and diseases seen in general practice.  
However,  our study has several limitations that should 
be considered.  First,  the proportion of patients with 
metabolic and endocrine diseases was relatively high,  
which might reduce the generalizability of the results.  
Second,  since our results were obtained using retro-
spective data from a single center in Japan,  a multi-
center study with a larger population is necessary.  
Third,  the ALP measurements were performed accord-
ing to the JSCC standard,  not according to the 
International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC).  This could have affected 
the data for serum ALP,  since intestinal and placental 
isozymes and blood types are known to modify the ALP 
levels standardized by the JSCC method [27].  Fourth,  
since the patients’ chief complaints and primary dis-
eases were obtained from electronic medical records by 
a limited number of researchers,  the possibility of sam-
pling bias cannot be completely excluded.  Despite these 
limitations,  considering that the patients’ serum BAP/
ALP ratios were correlated with aging and nutrition 
factors,  we propose that the BAP/ALP ratio can also be 
a useful predictor of important geriatric conditions.  
Further cohort studies are needed to reveal in-depth 
relationships between the BAP/ALP ratio and systemic 
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disorders in general medicine.
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